This is a MUST READ from Zachary Brennen at RAPS/Regulatory Focus on the review and potential reauthorization of the controversial priority review voucher (PRV) program...
Read More
This morning the FDA announced its approval of eteplirsen (brand name, Exonys 51) for the treatment of Duchenne muscular dystrophy (DMD) in boys “who have a...
Read More
Citron Research, a stock-commentary website, has dropped a (another) bomb on Questcor Pharmaceuticals (QCOR). According to Citron’s latest research, QCOR’s...
Read More
A big HT to the neurodiversity weblog on this story. The medical license of Mark Geier, MD, PhD—whose dubious studies of and conclusions about autism (particularly with...
Read More
They seemed like good, though not particularly original, ideas at the time: Initiate a med-pharma blog and inaugurate the coming new year with the top 10 stories from...
Read More
A politically influential Florida chiropractor wants Mark and David Geier, proponents of the debunked link between the vaccine preservative thimerosal and autism and...
Read More